Robin L. Jones, MBBS, MRCP, MD, Institute of Cancer Research, London, UK, discusses the results of the Phase III MANTRA (NCT04979442) trial investigating safety and efficacy of milademetan (MDM2 inhibitor) versus trabectedin in patients with pretreated unresectable or metastatic dedifferentiated (DD) liposarcoma. Median progression-free survival (PFS) was numerically but not significantly higher in the milademetan arm; and the objective response rate (ORR) and disease control rate (DCR) were comparable between the two arms. No Grade 5 treatment-emergent adverse events (TEAEs) occurred in the milademetan arm, and 5 (6.3% of patients) occurred in the trabectedin arm. In the milademetan arm, dose reductions due to TEAEs were higher than the trabectedin arm (44.2 vs 29.1%), but discontinuation rates lower (11.6 vs 19.0%). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
